NeoGenomics Inc (NEO)

[surf1944]

7:34AM NeoPharm beats on top and bottom lines; sees Q1 revs slightly below ests; Q1 EPS slightly above; sees both FY13 EPS and revs in-line with consensus (NEO) 2.85 : Reports Q4 net loss of $113K or EPS of $0.00 vs ($0.01) CIQ est; revs increased 16% YoY to $14.9 mln vs 14.7 mln CIQ est.
Fourth Quarter 2012 Highlights:

35% Test Volume Growth
16% Revenue Growth
36% Increase in Adjusted EBITDA
2013 Guidance:
Q1:
Sees Q1 revs of $15.3 -16.0 mln vs $16.4 mln CIQ est
sees Q1 EPS of $0.00-0.01 vs $0.00 CIQ est.
FY13
Sees FY13 revs of $68-73 mln vs $70.8 mln CIQ est
sees FY13 EPS of $0.03-0.05 vs $0.04 CIQ est.